Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01XEO
|
||||
| Former ID |
DIB007323
|
||||
| Drug Name |
Debio-0824
|
||||
| Synonyms |
Debio-0824; ShK-186; Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One
|
||||
| Indication | Psoriatic arthritis [ICD9: 696; ICD10:L40.5, M07] | Phase 1 | [1] | ||
| Company |
Kineta
|
||||
| Target and Pathway | |||||
| Target(s) | Potassium voltage-gated channel subfamily A member 3 | Target Info | Inhibitor | [2] | |
| Reactome | Voltage gated Potassium channels | ||||
| WikiPathways | Potassium Channels | ||||
| BDNF signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02446340) Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers. U.S. National Institutes of Health. | ||||
| REF 2 | Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.